Quentec Asset Management Has Decreased Its Ultratech (UTEK) Position; Broadfin Capital Has Increased La Jolla Pharmaceutical Co (LJPC) Position By $1.08 Million

September 17, 2017 - By Kurt Siggers

Broadfin Capital Llc increased La Jolla Pharmaceutical Co (LJPC) stake by 4.37% reported in 2016Q4 SEC filing. Broadfin Capital Llc acquired 63,263 shares as La Jolla Pharmaceutical Co (LJPC)’s stock rose 79.23%. The Broadfin Capital Llc holds 1.51 million shares with $26.48M value, up from 1.45M last quarter. La Jolla Pharmaceutical Co now has $696.45M valuation. The stock increased 0.32% or $0.1 on September 15, reaching $31.48. About 1.23M shares traded or 304.02% up from the average. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has risen 128.65% since September 17, 2016 and is uptrending. It has outperformed by 111.95% the S&P500.

Quentec Asset Management Llc decreased Ultratech Inc (UTEK) stake by 35.3% reported in 2016Q4 SEC filing. Quentec Asset Management Llc sold 203,606 shares as Ultratech Inc (UTEK)’s stock rose 4.69%. The Quentec Asset Management Llc holds 373,263 shares with $8.95M value, down from 576,869 last quarter. Ultratech Inc now has $823.53M valuation. It closed at $30.23 lastly. It is down 51.23% since September 17, 2016 and is uptrending. It has outperformed by 34.53% the S&P500.

Since May 5, 2017, it had 0 insider purchases, and 3 sales for $1.72 million activity. On Thursday, May 11 Ghosh Dave sold $806,886 worth of Ultratech, Inc. (NASDAQ:UTEK) or 26,380 shares.

Quentec Asset Management Llc increased Lumentum Hldgs Inc stake by 509,206 shares to 782,722 valued at $30.25M in 2016Q4. It also upped 8Point3 Energy Partners Lp stake by 187,458 shares and now owns 1.49M shares. Cypress Semiconductor Corp (NASDAQ:CY) was raised too.

Among 3 analysts covering Ultratech (NASDAQ:UTEK), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Ultratech had 5 analyst reports since October 13, 2015 according to SRatingsIntel. The firm has “Hold” rating by Stifel Nicolaus given on Tuesday, October 13. The firm has “Hold” rating by Benchmark given on Friday, February 3. The stock has “Neutral” rating by B. Riley & Co on Friday, October 23.

Investors sentiment decreased to 0.01 in 2016 Q4. Its down 1.06, from 1.07 in 2016Q3. It worsened, as 25 investors sold UTEK shares while 43 reduced holdings. 19 funds opened positions while 39 raised stakes. 23.88 million shares or 1.09% less from 24.14 million shares in 2016Q3 were reported. Neuberger Berman Ltd Liability Co holds 0.07% in Ultratech, Inc. (NASDAQ:UTEK) or 2.03M shares. State Of Wisconsin Invest Board accumulated 0.04% or 357,377 shares. Price T Rowe Md has invested 0% in Ultratech, Inc. (NASDAQ:UTEK). Tci Wealth Advsr reported 0% in Ultratech, Inc. (NASDAQ:UTEK). Creative Planning holds 300 shares or 0% of its portfolio. Quentec Asset Management Lc holds 373,263 shares or 1% of its portfolio. Fortaleza Asset Management holds 0.29% of its portfolio in Ultratech, Inc. (NASDAQ:UTEK) for 5,720 shares. Ironwood Investment Mgmt Ltd Liability Corp invested in 0.84% or 47,976 shares. Frontier Ltd Limited Liability Company holds 0.36% or 1.94M shares in its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Ultratech, Inc. (NASDAQ:UTEK). Pdts Ptnrs Llc holds 22,800 shares or 0.04% of its portfolio. Dimensional Fund Advsrs LP reported 1.74 million shares. Dupont Capital Management Corp invested in 5,299 shares. Barclays Public Limited Liability holds 431 shares. Moreover, Boston Partners has 0.01% invested in Ultratech, Inc. (NASDAQ:UTEK) for 454,980 shares.

Among 6 analysts covering La Jolla Pharmaceutical Company (NASDAQ:LJPC), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. La Jolla Pharmaceutical Company had 9 analyst reports since August 11, 2015 according to SRatingsIntel. As per Thursday, August 31, the company rating was maintained by Jefferies. As per Tuesday, February 9, the company rating was initiated by Cowen & Co. The firm earned “Hold” rating on Tuesday, August 11 by Zacks. The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) has “Buy” rating given on Tuesday, September 8 by Chardan Capital Markets. The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) has “Buy” rating given on Tuesday, May 24 by Lake Street. On Monday, July 24 the stock rating was maintained by Jefferies with “Buy”. The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) has “Buy” rating given on Wednesday, August 30 by J.P. Morgan. Jefferies maintained La Jolla Pharmaceutical Company (NASDAQ:LJPC) rating on Monday, June 12. Jefferies has “Buy” rating and $4000 target.

Broadfin Capital Llc decreased Teligent Inc New stake by 270,190 shares to 1.93 million valued at $12.77 million in 2016Q4. It also reduced Zogenix Inc stake by 115,900 shares and now owns 766,412 shares. Nevro Corp was reduced too.

Since March 23, 2017, it had 1 insider purchase, and 0 sales for $5.00 million activity. 149,254 shares were bought by TANG KEVIN C, worth $5.00M on Thursday, March 23.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com